Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL
Jing Deng(Guangdong Provincial Center for Disease Control and Prevention), Matthew S. Davids(Dana-Farber Cancer Institute), Stacey M. Fernandes(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Anthony Letai(Dana-Farber Cancer Institute), Elif Işık(Dana-Farber Cancer Institute)
Cited by 16
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k